Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Unstable Angina with Preserved Left Ventricular Systolic Function
Restricted accessResearch articleFirst published online October, 2023
Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Unstable Angina with Preserved Left Ventricular Systolic Function
The present study evaluated the clinical results of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment in patients with unstable angina (UA) with preserved left ventricular systolic function who underwent percutaneous coronary intervention (PCI) due to uncertainty regarding the long-term prognosis using ACEI or ARB. A total of 1627 UA patients with preserved left ventricular systolic function after PCI were enrolled. After propensity score matching, there were no differences in major adverse cardiovascular and cerebrovascular events (MACCEs) (hazard ratio (HR) = .860, 95% confidence interval (CI): .465–1.590, P = .630), all-cause death (HR = .334, 95% CI: .090–1.238, P = .101), nonfatal myocardial infarction (HR = 4.929, 95% CI: .576–42.195, P = .145), stroke (HR = 1.049, 95% CI: .208–5.290, P = .954) and target vessel revascularization (TVR) (HR = 1.276, 95% CI: .537–3.031, P = .581) between the ACEI and ARB groups. In conclusion, prognoses were comparable between ACEI or ARB treatment in UA patients who had preserved left ventricular systolic function after PCI.
GiuglianoRPBraunwaldE. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2011;58:2342-2354.
2.
FoxKAPoole-WilsonPAHendersonRA, et al.Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. Lancet. 2002;360:743-751.
3.
SinghMRihalCSBergerPB, et al.Improving outcome over time of percutaneous coronary interventions in unstable angina. J Am Coll Cardiol. 2000;36:674-678.
4.
JneidHAndersonJLWrightRS, et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645-681.
5.
SOLVD InvestigatorsYusufSPittBDavisCEHoodWBCohnJN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6.
PfefferMABraunwaldEMoyeLA, et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327:669-677.
7.
FlatherMDYusufSKoberL, et al.Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Ace-inhibitor myocardial infarction collaborative group. Lancet. 2000;355:1575-1581.
8.
ColletJPThieleHBarbatoE, et al.2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
9.
PfefferMAMcMurrayJJVelazquezEJ, et al.Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
10.
ONTARGET InvestigatorsYusufSTeoKK, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
11.
DicksteinKKjekshusJGroup OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin ii antagonist losartan. Lancet. 2002;360:752-760.
12.
HaraMSakataYNakataniD, et al.Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin ii receptor blocker. Am J Cardiol. 2014;114:1-8.
13.
StraussMHHallAS. The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death. Prog Cardiovasc Dis. 2016;58:473-482.
14.
Blood Pressure Lowering Treatment Trialists CollaborationTurnbullFNealB, et al.Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-958.
15.
ProbstfieldJLO’BrienKD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol. 2010;105:10A-20A.
16.
DezsiCASzentesV. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk. Am J Cardiovasc Drugs. 2016;16:399-406.
17.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet. 1993;342:821-828.
18.
MontezanoACDinh CatANRiosFJTouyzRM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014;16:431.
19.
StraussMHHallAS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the arb-mi paradox. Circulation. 2006;114:838-854.
20.
GroenewegenHCvan der HarstPRoksAJ, et al.Effects of angiotensin ii and angiotensin ii type 1 receptor blockade on neointimal formation after stent implantation. Int J Cardiol. 2008;126:209-215.
21.
PetersSGottingBTrummelMRustHBrattstromA. Valsartan for prevention of restenosis after stenting of type b2/c lesions: the VAL-PREST trial. J Invasive Cardiol. 2001;13:93-97.
22.
GuneriSBarisNAytekinDAkdenizBPekelNBozdemirV. The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis: the role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus. Int Heart J. 2005;46:889-897.
23.
MiyazakiMSakonjoHTakaiS. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin ii antagonist in cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128:523-529.
24.
Raposeiras-RoubinSAbu-AssiECespon-FernandezM, et al.Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Rev Esp Cardiol2020;73:114-122.
25.
Cespon-FernandezMRaposeiras-RoubinSAbu-AssiE, et al.Angiotensin-converting enzyme inhibitors versus angiotensin ii receptor blockers in acute coronary syndrome and preserved ventricular ejection fraction. Angiology. 2020;71:886-893.
26.
AnnSHStraussMHParkGM, et al.Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention. Int J Cardiol. 2020;306:35-41.
